Cue Biopharma
61 hedge funds and large institutions have $35.1M invested in Cue Biopharma in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 18 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less ownership
Funds ownership: →
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
22% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 18
Holders
61
Holding in Top 10
–
Calls
$201K
Puts
$75K
Top Buyers
| 1 | +$2.62M | |
| 2 | +$873K | |
| 3 | +$873K | |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$841K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$198K |
Top Sellers
| 1 | -$2.26M | |
| 2 | -$811K | |
| 3 | -$485K | |
| 4 |
E
Ergoteles
New York
|
-$261K |
| 5 |
AC
Apogem Capital
New York
|
-$247K |